setmelanotide


( Last Updated : January 9, 2023)
Generic Name:
setmelanotide
Project Status:
Pending
Therapeutic Area:
Bardet-Biedl syndrome
Manufacturer:
Rhythm Pharmaceuticals, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0769-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Indicated in adult and pediatric patients 6 years of age and older with impairments in the MC4 receptor pathway due to genetic diseases, for the treatment of obesity and control of hunger In Bardet-Biedl syndrome (BBS)
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Indicated in adult and pediatric patients 6 years of age and older with impairments in the MC4 receptor pathway due to genetic diseases, for the treatment of obesity and control of hunger In Bardet-Biedl syndrome (BBS).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.